| abstract |
The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R 1 , R 2 , R 3 , R 5 or R 6 is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH 2 , O, S, SO, SO 2 , amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO 2 ; m is from 0 to 6; R 4 is OH, ═O (keto), NH 2 , or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO 2 . Optionally, R 5 and R 6 , together with the N—W bond of formula (I), comprise a macrocyclic ring. |